Search

Your search keyword '"Tanwandee, T"' showing total 235 results

Search Constraints

Start Over You searched for: Author "Tanwandee, T" Remove constraint Author: "Tanwandee, T"
235 results on '"Tanwandee, T"'

Search Results

1. Liver Dysfunction in Hyperthyroidism

2. Yellow Urticaria: A Systematic Review

3. Global multi-stakeholder endorsement of the MAFLD definition

4. A multi-society Delphi consensus statement on new fatty liver disease nomenclature

5. Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy

26. Unexpected findings from a large Asian HCV real life study

27. Real-world rates of hepatitis B surface antigen seroclearance in patients with chronic hepatitis B: a systematic review, conventional aggregated data meta-analysis and individual patient data meta-analysis

28. Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients

29. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

30. Pharmacokinetics, safety and antiviral activity of CMX157, a novel prodrug of tenofovir, administered as ascending multiple doses to healthy volunteers and Hepatitis B virus-infected subjects

31. Efficacy and safety of elbasvir/grazoprevir in treatment-naïve patients with chronic HCV GT 1, GT 4 and GT 6 infection (C-CORAL): a phase III randomized multinational clinical trial

32. HBeAg Seroconversion Rates after Five Years of Follow-Up in Patients Treated with Peginterferon Alfa-2a (40kd) in Neptune: Final Results of the Son of Neptune Long-Term Follow-Up Study

33. FRI-266 - Real-world rates of hepatitis B surface antigen seroclearance in patients with chronic hepatitis B: a systematic review, conventional aggregated data meta-analysis and individual patient data meta-analysis

34. THU-334 - Unexpected findings from a large Asian HCV real life study

35. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

36. P0612 : Interferon-gamma-inducible protein 10 promoter polymorphism related with end-of-treatment HBsAg levels and had complementary role in prediction of sustained virologic response to peginterferon in HBeAg-negative chronic hepatitis B: Multicenter study

39. Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin.

40. Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3.

41. Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.

43. Final results of ACHIEVE-2/3: Albinterferon alfa-2b plus ribavirin in treatment-naive patients with genotype 2/3 chronic hepatitis C.

45. 539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS

49. 424 RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY

Catalog

Books, media, physical & digital resources